Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

Share Price is delayed by 15 minutes
Get Live Data
28.80    0.00 (0.00%)
Bid:
27.80
Ask:
29.80
Spread: 2.00 (7.194%)
Market Cap: £76.28m
MIG5 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g Vct5 Share Chart

Directorate Change

17 Dec 2024 15:27

RNS Number : 4594Q
Maven Income and Growth VCT 5 PLC
17 December 2024
 

 

 

 

 

Maven Income and Growth VCT 5 PLC

 

Directorate Change

 

Appointment of Director

The Board of Maven Income and Growth VCT 5 PLC ("the Company") is pleased to announce the appointment of Brian Phillips as an independent Non-executive Director, with effect from 1 January 2025.

 

Brian is a member of the Institute of Chartered Accountants of Scotland and has over 35 years' Board level experience across industry, private equity investment and corporate finance. He is a member of the Advisory Boards of Harwood Private Equity III, IV, V and VI and is a partner in Imbiba, a small UK private equity business in the hospitality sector.

 

He is currently a non-executive director of AIM-quoted Tissue Regenix Group Plc, a healthcare business providing wound care products, and NAHL Group Plc, a provider of services to catastrophic injury sufferers, together with legal services. He is also a director of Motocaddy Limited, a distributor of golf products; Purple Dragon (Holdings) Limited, a high end family club operator; and Pet Mate Limited, a distributor of pet products and accessories.

 

Brian will also serve on the Company's Audit, Management Engagement, Nomination, Remuneration and Risk Committees, and will stand for election by Shareholders at the Annual General Meeting (AGM), currently scheduled to be held on 29 April 2025.

 

As at the date of this announcement, he has no current beneficial interest in the Company's Ordinary Shares and, in relation to his appointment, there is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 R.

 

Retirement of Director

As required by Listing Rule 9.6.11, the Company also advises that Gordon Humphries, who has served as an independent Non-executive Director since 7 February 2006 and as Chair of the Audit and Risk Committees, has decided to retire at the conclusion of the 2025 AGM and will not stand for re-election.

 

The Board would like to thank Gordon for his many years of dedication and commitment to the Company in his role as Non-executive Director and as Chair of the Audit and Risk Committees, including overseeing the appointment of Maven Capital Partners UK LLP as Manager and the Company adopting a new investment policy, allowing its transition from an AIM focussed VCT to a hybrid private equity and AIM investment vehicle. The Board wishes Gordon every success for the future.

 

Following Gordon's retirement, Brian Phillips will assume the role of Chair of the Audit and Risk Committees.

 

 

 

Maven Capital Partners UK LLP

Company Secretary

 

17 December 2024

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEDLFFZLLLFBE
Date   Source Headline
20th May 202610:20 amRNSAdmission of Further Securities to Trading
15th May 202610:10 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:39 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20264:10 pmRNSTransaction in Own Shares
28th Apr 20263:55 pmRNSResult of AGM
28th Apr 20261:35 pmRNSResult of AGM
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:30 amRNSAdmission of Further Securities to Trading
14th Apr 202611:11 amRNSIssue of Equity
8th Apr 20269:35 amRNSAdmission of Further Securities to Trading
27th Mar 20265:07 pmRNSOffer for Subscription - Fully Subscribed
25th Mar 202610:59 amRNSAdmission of Further Securities to Trading
25th Mar 20267:00 amRNSAnnual Financial Report
24th Mar 202612:13 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSUnaudited Net Asset Value
3rd Mar 20264:31 pmRNSTransaction in Own Shares - correction
27th Feb 20265:04 pmRNSTransaction in Own Shares
26th Feb 20264:53 pmRNSTransaction in Own Shares
26th Feb 20269:15 amRNSDividend Declaration
18th Feb 20265:01 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:11 amRNSDirector/PDMR Shareholding
17th Feb 202610:58 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:13 amRNSAdmission of Further Securities to Trading
16th Jan 20269:47 amRNSIssue of Equity
14th Jan 20262:44 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202511:15 amRNSDirector/PDMR Shareholding
16th Dec 202510:30 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:45 pmRNSResult of General Meeting
7th Oct 20254:15 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:11 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:17 pmRNSStatement re Dividend Investment Scheme
17th Jul 20253:21 pmRNSHalf-year Report
16th Jul 20255:33 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:50 pmRNSStatement re Unaudited NAV and Interim Dividend
14th May 20254:46 pmRNSTransaction in Own Shares
9th May 20259:59 amRNSIssue of Equity
6th May 202511:55 amRNSIssue of Equity
2nd May 20251:27 pmRNSUnaudited NAV - Dividend Investment Scheme
29th Apr 20253:20 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
15th Apr 20259:32 amRNSDirector/PDMR Shareholding
4th Apr 20256:22 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:14 pmRNSDirector/PDMR Shareholding
27th Mar 20251:09 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.